TTY Biopharm Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	4yrs
Promedio de permanencia en la Junta Directiva	8.3yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Mar 15

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Feb 25

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Feb 07

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

Jan 19

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 10

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Nov 25

CEO

TTY Biopharm no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kuo-Chiang Chang	Chief Financial Officer	less than a year	sin datos	sin datos
Shu-Wen Wang	Accounting Officer	9.2yrs	sin datos	sin datos
Shu-Fen Huang	Chief Legal & Compliance Officer	2.5yrs	sin datos	sin datos
Wei-Ying Yin	Director of Public Affairs Department	no data	sin datos	sin datos
Jen-Yang Chang	Chief Human Resource Officer	5.4yrs	sin datos	sin datos
Si-Yuan Yang	Senior Vice President	15.4yrs	sin datos	sin datos
Allen Chu	Head of Intensive Care Business Unit	no data	sin datos	sin datos
Ching-Lan Hou	General Manager	2.5yrs	sin datos	sin datos
Yung-Min Chiang	Chief Auditor	no data	sin datos	sin datos

4.0yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 4105 se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Tze-Kaing Yang	Director	8.3yrs	sin datos	sin datos
Chuan-Quan Lin	Chairman of the Board	13.3yrs	sin datos	0.084% NT$ 15.5m
Ming-Ling Hsueh	Independent Director	8.3yrs	sin datos	sin datos
Wen-Hwa Chang	Vice Chairman	29.3yrs	sin datos	7.56% NT$ 1.4b
Ying-Ying Liao	Director	8.3yrs	sin datos	sin datos
Carl Hsiao	Representative Director	5.6yrs	sin datos	0.35% NT$ 65.1m
Ming-Dao Chang	Independent Director	less than a year	sin datos	sin datos
An-Li Zheng	Independent Director	less than a year	sin datos	sin datos
Shi-Chang Xu	Representative Director	less than a year	sin datos	sin datos

8.3yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: La junta directiva de 4105 se considera experimentada (7.8 años de antigüedad promedio).

TTY Biopharm Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

TTY Biopharm Company Limited Announces Change of CFO and Financial Officer

TTY Biopharm Company Limited, Annual General Meeting, May 30, 2024

Less than half of directors are independent

TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022

Less than half of directors are independent

TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee

Recent updates

Second quarter 2024 earnings released: EPS: NT$1.05 (vs NT$1.24 in 2Q 2023)

TTY Biopharm Company Limited to Report Q2, 2024 Results on Aug 08, 2024

Now 20% undervalued after recent price drop

TTY Biopharm Company Limited Approves Cash Dividend for the Year 2023

Price target decreased by 9.3% to NT$78.00

Now 20% undervalued after recent price drop

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

TTY Biopharm Company Limited to Report Q1, 2024 Results on May 07, 2024

Upcoming dividend of NT$3.50 per share

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Dividend increased to NT$3.50

TTY Biopharm Company Limited Announces Change of CFO and Financial Officer

TTY Biopharm Company Limited, Annual General Meeting, May 30, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 10% to NT$86.00

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to NT$84.50

TTY Biopharm Company Limited Announces Decision Rendered by the Supreme Court for Validity of the Risperidone Development Agreement Between the Company and Center Laboratories, Inc

Now 20% undervalued after recent price drop

Upcoming dividend of NT$3.40 per share at 4.3% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to NT$71.50

Price target increased to NT$79.50

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$3.00 per share

TTY Biopharm Company Limited Announces Dividend Distribution, Payable on August 15, 2022

TTY Biopharm Company Limited Announces Cash Dividend for the Year 2021

Price target decreased to NT$73.00

Less than half of directors are independent

TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee

Price target decreased to NT$73.67

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Third quarter 2021 earnings released: EPS NT$1.02 (vs NT$0.90 in 3Q 2020)

Upcoming dividend of NT$4.00 per share

Price target increased to NT$80.00

Consensus EPS estimates fall to NT$2.87

Second quarter 2021 earnings released: EPS NT$0.13 (vs NT$0.75 in 2Q 2020)

Price target increased to NT$80.20

Price target increased to NT$80.20

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$0.82 (vs NT$1.02 in 1Q 2020)

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Tty Biopharm Company Limited Proposes Dividend for the Period January 1, 2020 to December 31, 2020

Full year 2020 earnings released: EPS NT$3.72 (vs NT$3.62 in FY 2019)

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

PAION AG Enters into License Agreement with TTY Biopharm Company Limited

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Price target lowered to NT$73.50

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

TTY Biopharm Company Limited, Annual General Meeting, Jun 09, 2021

New 90-day low: NT$61.40

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

New 90-day low: NT$68.10

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

TTY Biopharm Company Limited Announces Executive Changes, with Effect from January 20, 2021

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS NT$0.89

Market bids up stock over the past week

New 90-day high: NT$84.30

Analysts lower revenue estimates to NT$4.14b

New 90-day low: NT$66.20

Price target lowered to NT$79.33